The promise of stem cell research, once deemed a scientists' dream, has turned the corner into real marketed products and looks to soon be a multi-billion-dollar industry. Randal Mills, the chief executive officer of Osiris Therapeutics tells the Chicago Tribune's Bruce Japsen about stem cell products already on the market and how more are soon coming to physicians and their patients.
